Our Projects
Decarbonise faster
With Net Zero fast approaching, we’ve designed an advanced new HGV that makes it possible for heavy-duty fleets to go carbon-free. Generating energy from hydrogen (with water the only by-product), fuel cell technology is what makes zero-emission trucking possible. Unlike BEVs, our hydrogen-powered vehicles can refuel in as little as ten minutes and go up to 500km between stops. We’ve used fuel cell technology to create one of the most robust and sophisticated systems on the market.
We are working with HVS to facilitate £120M debt finance facility to enable them to develop their technology and build the first road-going vehicles.
An affordable sea public transport model inspired by the airline industry, efficiency and standards.
Optimal propulsion and hull design enabling luxury, comfort, economy and sea keeping beyond existing options.
We are raising $105M debt finance to enable Sea Horse Yachts to begin building yachts in a bespoke facility on the Maldives.
Bespoke Construction Group offers comprehensive building services, including design, pre-construction planning, project management, construction, and post-construction support.
Helping Bespoke to raise their next project finance facility to allow them to build 12 new homes on acquired land.
An existing development in Texas with 392 apartments to be redeveloped and modernised.
We are facilitating a re-finance of $10M plus additional refurbishment finance of up to $50M.
MedTecFlo “MTF” is a UK-based MedTech SME, with a core team of eight. Overseen by an ex-GSK (main board) industry specialist. Clinically supervised by one of the UK’s leading professors in respiratory medicine. Our Product works 60 times faster than any tablet mix of ibuprofen and paracetamol.
We are sourcing equity finance for MedTecFlo to enable them to develop the technology and take the product to market via a joint venture with big pharma.
New Solutions for Oncology
Tosk Inc. is a biopharmaceutical company dedicated to improving outcomes for cancer patients by developing new drugs to improve the safety and efficacy of existing therapies and to block the activity of cancer genes.
We are helping Tosk to source up to $50M equity funding to develop their technology and complete trials to get FDA regulation.
